Small Cap Feast
Small Cap Feast – 25th October 2016
Dish of the Day:
No AIM Primary Today
No AIM Primary Today
Off the Menu:
Avarae Global Coins (AVR) delisting complete following a tender offer
Avarae Global Coins (AVR) delisting complete following a tender offer
What’s Cooking in the IPO Kitchen?
Filta— Schedule One from the provider of a number of services to national and independent commercial kitchen operators and owners. Targets early November listing. Capital raising plans as yet undisclosed
Van Elle—The geotechnical contractor to the UK construction market is hoping to come to AIM later this month
Ascot Lloyd— The UK IFA is also hoping to join AIM later this month. Ascot Lloyd’s strategy is to grow through a combination of organic growth and further targeted acquisitions.
Shoe Zone (SHOE.L) 142.5p £71.25m
FY 01Oct 16 trading update from the UK’s largest value footwear retailer. The Group has traded well in the second half of the year and expects to report revenues for the 52 week period of approximately £160 million (2016: £166.8 million), reflecting the continued planned closure of loss making stores. The Group ended the year with 510 stores, having opened 17 and closed 42 during the period. The Board expects pre-tax profit for the period to be broadly in line with expectations and marginally ahead of the prior year. FY16E revenue of £164.5m and PBT of £10.9m.
Beximco Pharmaceuticals (BXP.L) 45.5p £39.41m
The fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has received US Food and Drug Administration approval for Sotalol Hydrochloride, a generic version of the cardiovascular drug Betapace, following submission of an Abbreviated New Drug Application in June 2014. This is the second product from Beximco Pharma to be approved by the US FDA after Carvedilol, a prescription drug for treating hypertension, which was approved in July 2015. Expects Q1 2017 launch.
Valirx (VAL.L) 7p £5.83m
The life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, updated on its patents for clinical stage therapeutic compounds VAL201 and VAL401, which are currently in Phase I/II and Phase IIB clinical trials to treat prostate and lung cancer respectively. Patent approval for Val201 in Japan. A 3rd US patent has been allowed covering the use of VAL401 in the treatment of pancreatic adenocarcinoma.
Galileo Resources (GLR.L) 1.43p £2.77m
Update on Nevada projects. Ferber: A significant number of rock-chip samples (11 out of 23 samples) returned gold values exceeding 0.2 g/t. Seven of these 11 samples exceed 1.0 g/t with a high of 10.8g/t. ‘The Ferber intrusion-centred gold system is broadly similar to productive gold deposits elsewhere in north-central Nevada, where Carlin-style gold mineralisation and gold skarn mineralisation are genetically related to Late Eocene intrusions similar in age to the Ferber stock’. Silverton Project JV partner Orogen Gold plc commences drilling.
Alba Mineral Resources (ALBA.L) 0.32p £5.79m
Alba has completed a detailed gravity survey and soil sampling programme on its 100% owned prospecting licence (PL3824) in County Limerick in the Republic of Ireland. Survey completed over a total area of 400 ha., 240 gravity stations measured and the results from each station have now been sent to Alba’s consulting geophysicist for detailed analysis. 277 soil samples taken. Following initial analysis by portable XRF, anomalous samples to be dispatched to laboratory for detailed multi-element analysis.
Tekcapital (TEK.L) 36p £12.75m
The international provider of technology and intellectual property services, announced that Belluscura has concluded an oversubscribed private placement to raise approximately US$675,000, giving Belluscura a post-money valuation of US$5,250,000. Tekcapital now owns approximately 65% of the share capital of Belluscura. Use of proceeds includes regulatory, safety and quality expenses for medical products, including CE Marking and certification for European sales. Investors in the Private Placement include Nigel Wray and his family.
Swallowfield (SWL.L) 265p £44.69m
The specialist in the development, formulation, and supply of personal care and beauty products, announced that one of the products in its The Real Shaving Co. owned brand, was awarded a prestigious award at the GQ Grooming Awards. The brand’s ‘Sensitive Shave Gel’ won the Best New Shaving Gel at the awards ceremony. The Real Shaving Company was acquired by Swallowfield in May 2015 and is available at Waitrose, Sainsbury’s, Boots & online at: www.realshaving.com. FY Jun16E revs £67m, EPS 20.74p, Div 5.2p. 12.8x PE
Clinigen Group (CLIN.L) 738.5p £849.97m
The global pharmaceutical and services company, announced that its Idis Global Access division, has signed an exclusive supply agreement with BTG plc (LSE: BTG), a specialist healthcare company, to manage BTG’s critical care portfolio across the whole of Europe and now into new territories in Asia. This agreement extends the four-year partnership Clinigen has with BTG to provide early access programmes. First agreement that capitalises on the complementary nature of the Managed Access and Global Access divisions.
88 Energy (88E.L) 2.45p £95.4m
88 Energy has reached agreement regarding a placement to raise gross proceeds of A$11m to two US-based institutional investors. The net proceeds from the Placement will be used to strengthen the Company’s balance sheet ahead of the upcoming drilling of Icewine#2 in Q2017, pursue complementary growth opportunities in Alaska and for general working capital purposes. The placing price is A$0.04 equivalent to ~£0.025. In addition, 137.5m 5 year unlisted options at an exercise price of A$0.055 (equivalent to ~£0.034) will be issued to the investors.
Share (SHRE.L) 27.5p £39.5m
Share, which operates The Share Centre Limited, a UK independent stockbroker, has provided an update on trading, and announced an agreement to acquire a book of 8,000 customer accounts (predominantly ISAs) containing approximately £200m of assets under administration. The acquisition is expected to complete in April 2017. The consideration was not disclosed. Q3 was in line with management expectations, with revenues excluding interest increasing by 7% year-on-year, up from the 1% increase for the first half of the year.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.